Health Technology · Pharmaceuticals: Major · NSE: WOCKPHARMA · data 2026-10-09

Wockhardt Limited

Health check: Average (4.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,996.4

Market cap

₹33,002 cr

P/E

79.3

P/B

—

ROE

4.6%

ROCE

5.3%

Debt / equity

0.45

Dividend yield

0.00%

1-year return

41.7%

52-week high

₹2,422.3

52-week low

₹1,086.7

Operating margin

13.8%

Growth

Revenue (last 12 months)	₹3,564 cr
Net profit (last 12 months)	₹409 cr
Sales growth, 3 years (yearly)	7.8%
Profit growth, 3 years (yearly)	—

Chart patterns

Double bottom — forming (key level ₹2,067.7)

Similar companies

Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO) · Emcure Pharmaceuticals Limited (EMCURE) · Neuland Laboratories Ltd. (NEULANDLAB) · Piramal Pharma Limited (PPLPHARMA)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open WOCKPHARMA in NSE Scanner →